<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998620</url>
  </required_header>
  <id_info>
    <org_study_id>XMX-HBV-001</org_study_id>
    <nct_id>NCT01998620</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis</brief_title>
  <official_title>Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Hisun Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Hisun Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an evaluation of adenosine methionine for treatment of chronic hepatitis b patients
      with cholestasis efficacy and safety of multicenter, randomized, open label clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      evaluation of adenosine methionine for treatment of chronic hepatitis b patients with
      cholestasis efficacy and safety
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>levels of serum total bilirubin declined from baseline</measure>
    <time_frame>2 weeks</time_frame>
    <description>levels of serum total bilirubin declined from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline Phosphatase</measure>
    <time_frame>10 weeks</time_frame>
    <description>Alkaline Phosphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gamma-Glutamyl Transpeptidase</measure>
    <time_frame>10 weeks</time_frame>
    <description>Gamma-Glutamyl Transpeptidase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>level of serum direct bilirubin decline from baseline</measure>
    <time_frame>2 weeks, 6 weeks, 10 weeks</time_frame>
    <description>level of serum direct bilirubin decline from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of serum bile acids decline from baseline</measure>
    <time_frame>2 weeks, 6 weeks, 10 weeks</time_frame>
    <description>level of serum bile acids decline from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glutamic pyruvic transaminase</measure>
    <time_frame>2 weeks, 6 weeks, 10 weeks</time_frame>
    <description>glutamic pyruvic transaminase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glutamic oxaloacetic transaminase</measure>
    <time_frame>2 weeks, 6 weeks, 10 weeks</time_frame>
    <description>glutamic oxaloacetic transaminase</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Ademetionine 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ademetionine 2000mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ademetionine 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ademetionine 1000mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ademetionine 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no treatment in first 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ademetionine 2</intervention_name>
    <description>Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks</description>
    <arm_group_label>Ademetionine 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ademetionine 1</intervention_name>
    <description>Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks</description>
    <arm_group_label>Ademetionine 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ademetionine 3</intervention_name>
    <description>no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks</description>
    <arm_group_label>Ademetionine 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. from 18-65 years old

          2. diagnosed as hepatitis B, previous has HBV or HBsAg(+)&gt;6 months, and now HBsAg or HBV
             DNA(+)

          3. with intrahepatic cholestasis: meet EASL 2009 diagnoses criteria ALP&gt;1.5ULN and
             GGT&gt;3ULN or STB&gt;2ULN

        Exclusion Criteria:

          1. liver mass, liver carcinoma

          2. liver failure

          3. non-hepatic diseases caused jaundice

          4. obstructive jaundice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Public Health Clinical Center Affiliated to Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liang Chen</last_name>
    <phone>00862137990333</phone>
    <email>chenlian@shaphl.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Public Health Clinical Center Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Chen, Doctor</last_name>
      <phone>00862137990333</phone>
      <email>chenlian@shaphl.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2013</study_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Cholestasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

